Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (176)	8/11/2001 2:36:24 AM
From: nigel bates	Read Replies (1) \| Respond to of 360

genomeweb.com ...the president’s order will have little effect on the growth of genomics companies in the short term. But he suggested it might slow the handful of genomic labs that either have struck alliances to pursue stem-cell research or those who plan to. Companies that have already forged these partnerships include MetriGenix and Neuralstem, who announced their alliance this week to co-develop a series of neurochips as low-density oligonucleotide microarrays for researchers studying various central nervous system disorders. Both companies said they expect the market for these and other custom, inexpensive microarrays to increase exponentially into the billions of dollars during the next decade. MetriGenix, which was spun off from Gene Logic in July to stake an early position in the microarray market and capitalize on its Flow-thru technology chip, already is planning to develop similar custom microarrays for proteomics and cardiovascular researchers, MetriGenix President and CEO Drew O’Beirne said in an interview with GenomeWeb...